GENETIC ANALYSIS NK -60 (8V8) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has a cash flow conversion efficiency ratio of 0.297x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€8.04 Million ≈ $9.40 Million USD) by net assets (€27.08 Million ≈ $31.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 8V8 net asset quality score to measure how much of total assets are equity-financed.
GENETIC ANALYSIS NK -60 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 8V8 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
GENETIC ANALYSIS NK -60 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scisparc Ltd
NASDAQ:SPRC
|
-0.442x |
|
Gore Street Energy Storage Fund Plc
LSE:GSF
|
0.011x |
|
Nexion Group Ltd
AU:NNG
|
-0.152x |
|
Marin Software Inc
NASDAQ:MRIN
|
-0.305x |
|
Opawica Explorations Inc
V:OPW
|
-0.022x |
|
SKONEC Entertainment Co. Ltd.
KQ:276040
|
-0.163x |
|
BEYOND FRAMES ENTMT AB
F:8WP
|
0.111x |
|
St James Gold Corp
V:LORD
|
0.001x |
Annual Cash Flow Conversion Efficiency for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual cash flow conversion efficiency of GENETIC ANALYSIS NK -60 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 8V8 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €27.08 Million ≈ $31.66 Million |
€2.40 Million ≈ $2.81 Million |
0.089x | +117.16% |
| 2024-12-31 | €22.49 Million ≈ $26.30 Million |
€-11.62 Million ≈ $-13.59 Million |
-0.517x | +4.04% |
| 2023-12-31 | €32.00 Million ≈ $37.41 Million |
€-17.23 Million ≈ $-20.15 Million |
-0.539x | -22.17% |
| 2022-12-31 | €44.14 Million ≈ $51.60 Million |
€-19.46 Million ≈ $-22.75 Million |
-0.441x | -15.07% |
| 2021-12-31 | €72.09 Million ≈ $84.28 Million |
€-27.62 Million ≈ $-32.29 Million |
-0.383x | -- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more